Warner-Lambert Rezulin
Executive Summary
FDA's Endocrine & Metabolic Drugs Advisory Committee will meet May 19 to hear FDA's presentation of data and to discuss the rationale behind the March 21 withdrawal of the type 2 diabetes therapy troglitazone from the U.S. market (1"The Pink Sheet" March 27, p. 5). The committee will meet at the Holiday Inn in Bethesda, Md. at 10 a.m